MX2018011685A - Proceso para formulaciones solidas de mesalazina. - Google Patents

Proceso para formulaciones solidas de mesalazina.

Info

Publication number
MX2018011685A
MX2018011685A MX2018011685A MX2018011685A MX2018011685A MX 2018011685 A MX2018011685 A MX 2018011685A MX 2018011685 A MX2018011685 A MX 2018011685A MX 2018011685 A MX2018011685 A MX 2018011685A MX 2018011685 A MX2018011685 A MX 2018011685A
Authority
MX
Mexico
Prior art keywords
mesalazine
relates
present
granulate
solid formulations
Prior art date
Application number
MX2018011685A
Other languages
English (en)
Inventor
Labruzzo Carla
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56551461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018011685(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MX2018011685A publication Critical patent/MX2018011685A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Luminescent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a un proceso para preparar formas farmacéuticas sólidas que comprenden una cantidad de mesalazina comprendida entre 75 y 95%, es decir, entre 1000 y 1600 mg de fármaco por unidad de dosificación. Aún más, la presente invención se refiere a un granulado y/o tabletas obtenidas/obtenibles con el proceso de acuerdo con la invención, de preferencia recubiertas para permitir la liberación controlada del fármaco. Finalmente, la presente invención se refiere al uso del granulado y/o las tabletas como medicamento, de preferencia para el tratamiento de patologías inflamatorias crónicas que de preferencia afectan el tracto intestinal.
MX2018011685A 2016-04-05 2017-04-04 Proceso para formulaciones solidas de mesalazina. MX2018011685A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUA2016A002293A ITUA20162293A1 (it) 2016-04-05 2016-04-05 Processo per formulazioni solide di mesalazina
PCT/IB2017/051907 WO2017175123A1 (en) 2016-04-05 2017-04-04 Process for mesalazine solid formulations

Publications (1)

Publication Number Publication Date
MX2018011685A true MX2018011685A (es) 2018-12-19

Family

ID=56551461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011685A MX2018011685A (es) 2016-04-05 2017-04-04 Proceso para formulaciones solidas de mesalazina.

Country Status (21)

Country Link
US (2) US11504331B2 (es)
EP (1) EP3439637B1 (es)
CN (2) CN117442562A (es)
AU (1) AU2017247783B2 (es)
BR (1) BR112018070521A2 (es)
CL (1) CL2018002765A1 (es)
CO (1) CO2018010142A2 (es)
DK (1) DK3439637T3 (es)
ES (1) ES2924881T3 (es)
HR (1) HRP20221073T1 (es)
HU (1) HUE059531T2 (es)
IT (1) ITUA20162293A1 (es)
LT (1) LT3439637T (es)
MA (1) MA43793B1 (es)
MD (1) MD3439637T2 (es)
MX (1) MX2018011685A (es)
PL (1) PL3439637T3 (es)
PT (1) PT3439637T (es)
RS (1) RS63492B1 (es)
SI (1) SI3439637T1 (es)
WO (1) WO2017175123A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
WO1998023767A1 (fr) 1996-11-25 1998-06-04 Takara Shuzo Co., Ltd. Antibiotique tkr 459, son procede de production et micro-organisme
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
WO2000044353A1 (de) * 1999-01-29 2000-08-03 Losan Pharma Gmbh Pharmazeutische zusammensetzungen
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
AR036797A1 (es) * 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
KR100859358B1 (ko) 2001-10-15 2008-09-22 훼링 비.브이. 궤양성 대장염 및 크론병의 치료에 유용한5-아미노살리실산을 포함하는 약학적 조성물의 제조 방법
US20090017110A1 (en) 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
EP2425826A1 (en) 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
AU2011300642B2 (en) 2010-09-10 2015-02-26 Pharmazell Gmbh Process for producing crystalline 5-aminosalicylic acid
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
JP2019513800A (ja) * 2016-04-19 2019-05-30 フェリング ベスローテン フェンノートシャップ メサラジンの経口薬学的組成物

Also Published As

Publication number Publication date
US20190151245A1 (en) 2019-05-23
MA43793B1 (fr) 2022-09-30
DK3439637T3 (da) 2022-08-29
PL3439637T3 (pl) 2022-09-26
MA43793A (fr) 2018-11-28
PT3439637T (pt) 2022-08-30
ITUA20162293A1 (it) 2017-10-05
US20230104254A1 (en) 2023-04-06
HUE059531T2 (hu) 2022-11-28
ES2924881T3 (es) 2022-10-11
CN117442562A (zh) 2024-01-26
EP3439637B1 (en) 2022-06-01
CL2018002765A1 (es) 2019-01-18
HRP20221073T1 (hr) 2022-11-25
RS63492B1 (sr) 2022-09-30
AU2017247783B2 (en) 2022-12-22
WO2017175123A1 (en) 2017-10-12
AU2017247783A1 (en) 2018-10-25
BR112018070521A2 (pt) 2019-01-29
CN109069428A (zh) 2018-12-21
EP3439637A1 (en) 2019-02-13
MD3439637T2 (ro) 2022-10-31
LT3439637T (lt) 2022-09-12
SI3439637T1 (sl) 2022-10-28
CO2018010142A2 (es) 2018-10-22
US11504331B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
PL3793534T3 (pl) Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EP3972691A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DRUG OVERDOSE
MX2018011685A (es) Proceso para formulaciones solidas de mesalazina.
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
MX2018003890A (es) Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine).
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
EP4052699A4 (en) MEDICINE IN SOLID PHARMACEUTICAL FORM ADMINISTERED ORALLY
MX364197B (es) Proceso de sintesis de hidroxi-triacilgliceroles y usos de los mismos para la prevencion y el tratamiento de enfermedades.
MX2017000384A (es) Forma de dosificacion en capsulas de succinato de metoprolol.
PH12016502540A1 (en) Pharmaceutical dosage forms
JOP20200005A1 (ar) تركيبات صيدلية
WO2016020936A3 (en) A novel oral gastroretentive pharmaceutical dosage form
PH12018500889A1 (en) Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine
MX2016017001A (es) Sistema multiparticulado de liberacion bifasica con prediccion de biodisponibilidad modificada de acemetacina.